Skip to content
Evigrade
MajorVitamin K antagonist anticoagulants×Non-steroidal anti-inflammatory drugs, propionic acid derivatives

Updated · Methodology

Mechanism

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the effects of coumarin-type anticoagulants for three reasons: dexketoprofen is highly bound to plasma proteins, inhibits platelet function and damages the gastroduodenal mucosa (dexketoprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dexketoprofen is 99% bound to plasma proteins, and as a non-selective NSAID it inhibits prostaglandin synthesis, inhibits platelet aggregation and prolongs bleeding time (AEMPS). Acenocoumarol acts through vitamin K, which the liver needs for gamma-carboxylation of the prothrombin complex factors. With NSAIDs, the risk of bleeding on acenocoumarol rises, including gastrointestinal bleeding (acenocoumarol SmPCs, AEMPS).

Symptoms

The main risk is bleeding, above all from the stomach and intestine. With non-steroidal anti-inflammatory drugs (NSAIDs), gastrointestinal bleeding, ulceration and perforation can occur at any time during treatment, with or without warning symptoms, and can be fatal (dexketoprofen summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk is higher with high doses, in older people and in people with a history of ulcer, especially if it was complicated by bleeding or perforation (AEMPS). Bleeding is the main sign of an excessive acenocoumarol effect. The most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, vomiting blood, gastrointestinal, uterine, nose and gum bleeding and bleeding into the joints (acenocoumarol SmPC, overdose section, AEMPS).

Management

Both summaries of product characteristics (SmPCs) advise against the combination. The acenocoumarol SmPC advises against NSAIDs unless the combination is strictly indicated (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The dexketoprofen SmPC advises against combining dexketoprofen with warfarin, other coumarins and heparins (dexketoprofen SmPC, AEMPS). If the combination cannot be avoided, strict clinical control and laboratory monitoring are needed (dexketoprofen SmPC, AEMPS). Use close and frequent coagulation checks with the international normalised ratio (INR), for example twice a week, including after dexketoprofen is stopped (acenocoumarol SmPC, AEMPS). Dexketoprofen is not intended for long-term use. Limit treatment to the period of symptoms, do not exceed 75 mg a day, and start older people on 50 mg a day (dexketoprofen SmPC, AEMPS). Giving the lowest effective dose for the shortest time can reduce adverse reactions (AEMPS). Consider gastric protection with misoprostol or a proton pump inhibitor in people with a history of gastrointestinal disease and in people taking other drugs that raise the gastrointestinal risk. Stop dexketoprofen if gastrointestinal bleeding or ulceration occurs (AEMPS). For significant bleeding, stop acenocoumarol and give vitamin K1 5–10 mg intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, overdose section, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Dexketoprofen